Red ones are the drugs that are discontinued during trials and not
discussed
Table 2
Among the drugs mentioned in the table only aprepitant and fosaprepitant
could be marketed. Many others have been discontinued in the
developmental stage itself. Some trials are ongoing like Aprepitant for
Advanced small cell carcinoma(NCT04840004). Aprepitant was also tried
for Alcohol craving and PTSD(NCT00896038) which was completed but trial
results were not available. Interestingly aprepitant was also tried for
HIV infection which failed to show viral load
reduction.71 DNK-333 which was tried for IBS in two
trials [(NCT00699166) and (NCT00394173)] produced significant
subjective relief of symptoms in IBS but not with stool consistency
which was the primary endpoint of the trial. Vestipitant was another
agent tried for Tinnitus but showed no clinically significant
results.72Vofopitant was another drug tried for PTSD
but showed efficacy not better than
placebo.73Ibodutant another drug which was evaluated
for IBS showed better efficacy when compared to placebo in symptomatic
improvement when compared to placebo.74TA-5538 was
tried for overactive bladder in a trial in Japan and was discontinued
for undisclosed reasons. SSR 240600 was tried in a trial called BILADY
for which results were not published (NCT00564226). LY-686017 which was
tried for social anxiety disorder showed no significant difference in
Leibowitz social anxiety scale (LSAS) when compared to placebo
(NCT00191002).75 Orvepitant was tried for MDD but the
trial was terminated since seizures occurred in patients during the
trial period (NCT00880399). Rolapitant was studied for its effects in
PONV but the results of the trial were not published (NCT00539721).
Casopitant was another drug which was tried for a number of conditions,
its efficacy for overactive bladder was evaluated but terminated due to
undisclosed reasons (NCT00332319). The same drug was tried for
fibromyalgia and this trial was completed but results were not published
(NCT00264628). Similar is the case with primary insomnia
[(NCT00280423), (NCT00280436), (NCT00354809)]. For CINV the
manufacturers approached European medicines agency for marketing
authorisation application but withdrawn in September 2009 by the
manufacturers76 So again as like bradykinins the
modalities to target tachykinins were also not so straightforward other
than cases of PONV and CINV Even though research continues in this field
and successful drug development for other indications might become
feasible.